help with discussion

SHAREHOLDERS CRISIS COMMUNICATION 1

Subject: Failed BreathEZ Inhaler

Dear Shareholder,

On 22nd September 2022, as you may have already heard, we learnt about an incident

where a 21 years old asthmatic male attempted to use his BreatheEZ during an Asthma attack,

which failed. Luckily, 911 was called, and the patient is stable in a local hospital. The Chief

Resident at the hospital where the patient was admitted called our customer care department to

complain that the BreathEZ inhaler did not contain the active ingredient, which led to the

situation.

To uncover the cause and scope of the issue, we have launched a vigorous investigation

that will only end when the problem has been identified. Employees from the quality assurance

department are heavily engaged in assessing the products and establishing if the situation is a

particular case; it is widespread in other BreatheEZ products.

We highly recommend that if you know anyone using the BreatheEZ inhaler, visit any of

our stores around them for a quality assessment of their BreathEZ inhaler. This precaution

ensures that the problem does not happen to anyone else and puts their life at risk.

At this moment of uncertainty, I wish to thank you for your continued support, and we

urge you to remain calm as we investigate the situation we promise to communicate again as

soon we conclude the investigations.

Sincerely,

Heba Elwahsh

SHAREHOLDERS CRISIS COMMUNICATION 2

Chief Executive Officer

QuantaCare